BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 16909133)

  • 1. Genetic and epigenetic alterations on the short arm of chromosome 11 are involved in a majority of sporadic Wilms' tumours.
    Satoh Y; Nakadate H; Nakagawachi T; Higashimoto K; Joh K; Masaki Z; Uozumi J; Kaneko Y; Mukai T; Soejima H
    Br J Cancer; 2006 Aug; 95(4):541-7. PubMed ID: 16909133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wilms tumour histology is determined by distinct types of precursor lesions and not epigenetic changes.
    Fukuzawa R; Anaka MR; Heathcott RW; McNoe LA; Morison IM; Perlman EJ; Reeve AE
    J Pathol; 2008 Aug; 215(4):377-87. PubMed ID: 18484682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.
    Yuan E; Li CM; Yamashiro DJ; Kandel J; Thaker H; Murty VV; Tycko B
    Mol Cancer Res; 2005 Sep; 3(9):493-502. PubMed ID: 16179496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency and timing of loss of imprinting at 11p13 and 11p15 in Wilms' tumor development.
    Brown KW; Power F; Moore B; Charles AK; Malik KT
    Mol Cancer Res; 2008 Jul; 6(7):1114-23. PubMed ID: 18644976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic alteration at the DLK1-GTL2 imprinted domain in human neoplasia: analysis of neuroblastoma, phaeochromocytoma and Wilms' tumour.
    Astuti D; Latif F; Wagner K; Gentle D; Cooper WN; Catchpoole D; Grundy R; Ferguson-Smith AC; Maher ER
    Br J Cancer; 2005 Apr; 92(8):1574-80. PubMed ID: 15798773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell types expressing the Wilms' tumour gene (WT1) in Wilms' tumours: implications for tumour histogenesis.
    Pritchard-Jones K; Fleming S
    Oncogene; 1991 Dec; 6(12):2211-20. PubMed ID: 1722569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetics of Wilms' tumor.
    Coppes MJ; Egeler RM
    Semin Urol Oncol; 1999 Feb; 17(1):2-10. PubMed ID: 10073400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial predisposition to Wilms' tumour does not map to the short arm of chromosome 11.
    Grundy P; Koufos A; Morgan K; Li FP; Meadows AT; Cavenee WK
    Nature; 1988 Nov; 336(6197):374-6. PubMed ID: 2848199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic imprinting and Wilms' tumor.
    Moulton T; Chung WY; Yuan L; Hensle T; Waber P; Nisen P; Tycko B
    Med Pediatr Oncol; 1996 Nov; 27(5):476-83. PubMed ID: 8827077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis.
    Grundy P; Telzerow P; Moksness J; Breslow NE
    Med Pediatr Oncol; 1996 Nov; 27(5):429-33. PubMed ID: 8926924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Wilms' tumors and malformation complexes].
    Hata J; Fukuzawa R; Takata A; Kikuchi H
    Nihon Rinsho; 2000 Jul; 58(7):1419-25. PubMed ID: 10921316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular nature of genetic changes resulting in loss of heterozygosity of chromosome 11 in Wilms' tumours.
    Mannens M; Slater RM; Heyting C; Bliek J; de Kraker J; Coad N; de Pagter-Holthuizen P; Pearson PL
    Hum Genet; 1988 Dec; 81(1):41-8. PubMed ID: 2848758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p57K1P2 is expressed in Wilms' tumor with LOH of 11p15.5.
    Overall ML; Spencer J; Bakker M; Dziadek M; Smith PJ
    Genes Chromosomes Cancer; 1996 Sep; 17(1):56-9. PubMed ID: 8889507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased expression of the insulin-like growth factor-II gene in Wilms' tumor is not dependent on loss of genomic imprinting or loss of heterozygosity.
    Wang WH; Duan JX; Vu TH; Hoffman AR
    J Biol Chem; 1996 Nov; 271(44):27863-70. PubMed ID: 8910385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human p57(KIP2) defines a new imprinted domain on chromosome 11p but is not a tumour suppressor gene in Wilms tumour.
    Taniguchi T; Okamoto K; Reeve AE
    Oncogene; 1997 Mar; 14(10):1201-6. PubMed ID: 9121769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour.
    Ogawa O; Eccles MR; Szeto J; McNoe LA; Yun K; Maw MA; Smith PJ; Reeve AE
    Nature; 1993 Apr; 362(6422):749-51. PubMed ID: 8097018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Molecular genetics of Wilms' tumor].
    Papezová M; Mares J; Goetz P
    Cas Lek Cesk; 2001 Jun; 140(11):323-7. PubMed ID: 11431850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infrequent mutation of the WT1 gene in 77 Wilms' Tumors.
    Gessler M; König A; Arden K; Grundy P; Orkin S; Sallan S; Peters C; Ruyle S; Mandell J; Li F
    Hum Mutat; 1994; 3(3):212-22. PubMed ID: 8019557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imprinting, expression, and localisation of DLK1 in Wilms tumours.
    Fukuzawa R; Heathcott RW; Morison IM; Reeve AE
    J Clin Pathol; 2005 Feb; 58(2):145-50. PubMed ID: 15677533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour.
    Park S; Bernard A; Bove KE; Sens DA; Hazen-Martin DJ; Garvin AJ; Haber DA
    Nat Genet; 1993 Dec; 5(4):363-7. PubMed ID: 8298644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.